hVIVO (LON:HVO) Share Price Crosses Above 50-Day Moving Average – Time to Sell?

hVIVO plc (LON:HVO) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 7.81 and traded as high as GBX 9.10. hVIVO shares last traded at GBX 8.95, with a volume of 1,271,796 shares traded.

Wall Street Analyst Weigh In

HVO has been the topic of several research reports. Shore Capital Group reissued a “buy” rating on shares of hVIVO in a research note on Wednesday, April 22nd. Stifel Nicolaus reaffirmed a “hold” rating and issued a GBX 10 price objective on shares of hVIVO in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, hVIVO currently has an average rating of “Moderate Buy” and a consensus target price of GBX 15.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63. The business has a 50 day moving average price of GBX 7.81 and a two-hundred day moving average price of GBX 7.13. The company has a market cap of £59.89 million, a P/E ratio of -10.00 and a beta of 1.69.

hVIVO (LON:HVO) last posted its quarterly earnings results on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. The company had revenue of GBX 4,677 million for the quarter. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%. On average, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insider Activity

In other news, insider Brendan Buckley sold 2,017,000 shares of the firm’s stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of GBX 9, for a total value of £181,530. Corporate insiders own 4.95% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.